Ochre Bio GTM brain

category

market profile

• text: Chronic liver disease has limited curative options and severe constraints on transplant availability.
• text: Large pharmaceutical companies license human liver data and partner on multi-target liver drug discovery, as shown by GSK and Boehringer collaborations.

personas

• title: Pharma head of liver or cardiometabolic research
  pains:

  • Finding causal targets for advanced fibrosis and cirrhosis
  • Validating promising biology in relevant human tissue before expensive clinical studies
• title: Biopharma business development and licensing lead
  pains:

  • Securing differentiated liver assets and discovery collaborations
  • Assessing scientific, clinical and milestone risk in early-stage programs
• title: Pharma AI and translational science leader
  pains:

  • Obtaining high-quality disease-specific human liver datasets
  • Connecting model predictions to experimentally tested targets

icp

• text: Large pharmaceutical groups investing in liver disease, fibrosis and cardiometabolic R&D are evidenced partners, including Boehringer Ingelheim and GSK.
• text: Biopharma discovery organizations with budgets for human data licensing, target validation or RNA programs are plausible partners; no minimum size is stated.

message pillars

• text: Start with human data and models to support translation.
• text: Unify patient and gene perturbation data for causal target discovery.
• text: Produce RNA therapies internally to accelerate research cycles.
• text: Anchor the company mission in addressing transplant need.

objections

• objection: Do the human model results translate to clinical efficacy?
  response: Review program-specific preclinical evidence and planned clinical studies; human tissue models do not establish clinical efficacy.
• objection: Is the platform relevant to our disease stage and targets?
  response: Discuss fit against the specific fibrosis, cirrhosis and target discovery programs before structuring a collaboration.

competitors

• name: Novo Nordisk
  why: Develops treatments in the liver disease market, including MASH.
• name: Akero Therapeutics
  why: Developed a late-stage MASH therapy, competing for liver disease treatment opportunities.

influencers

• name: Quin Wills
  url: https://www.bioescalator.ox.ac.uk/news-and-events/news/dr-quin-wills-appointed-as-ochre-bio-ceo
  why: Founder and CEO shaping the scientific and partnership narrative.
• name: Kim Branson
  why: GSK AI leader cited by Ochre on the value of its liver data.

keywords

• liver disease RNA therapeutics
• MASH fibrosis drug development
• human liver target discovery
• liver tissue disease models
• cirrhosis RNA therapy
• liver genomics data licensing

voice

• science led
• mission driven
• confident but translational

signals

• text: A pharma company expands MASH or fibrosis R&D and seeks novel targets.
• text: A discovery team seeks human liver data to train or validate AI models.

pricing

motion

channels

• pharma partnerships
• scientific networks
• LinkedIn
• industry press

confidence

Founders

• name: Quin Wills
  title: Founder/CSO
  role: Founder